J Korean Med Sci.  2014 Jul;29(7):980-984. 10.3346/jkms.2014.29.7.980.

Toxicity Profile of Temozolomide in the Treatment of 300 Malignant Glioma Patients in Korea

• Bae SH
• Park MJ
• Lee MM
• Kim TM
• Lee SH
• Cho SY
• Kim YH
• Kim YJ
• Park CK
• Kim CY

• KMID: 1789958
• DOI: http://doi.org/10.3346/jkms.2014.29.7.980

Abstract

This study evaluated the toxicity profiles of temozolomide in the treatment of malignant glioma as either concurrent or adjuvant chemotherapy. We retrospectively reviewed the medical records of 300 malignant glioma patients treated with temozolomide in two medical institutions in Korea between 2004 and 2010. Two hundred nine patients experienced a total of 618 toxicities during temozolomide therapy. A total of 84.8% of the 618 toxicities were Common Terminology Criteria for Adverse Events (CTCAE) grade 1 or 2, while 15.2% were grade 3 or 4. Among the hematologic toxicities, thrombocytopenia (13.7%), anemia (11.0%), and AST/ALT increases (7.0%) were common. Among the non-hematologic toxicities, nausea (44.3%), vomiting (37.0%), and anorexia (14.3%) were the three most common toxicities. There was no mortality due to temozolomide. Although temozolomide showed many types of toxicities, the majority of the toxicities were tolerable and of lower grade. Gastrointestinal troubles are the most common toxicities in Korean patients treated with temozolomide.

Keyword

Glioma; Temozolomide; Toxicity; Chemoradiotherapy; Chemotherapy, Adjuvant

MeSH Terms

Adolescent
Adult
Aged
Aged, 80 and over
Anorexia/etiology
Antineoplastic Agents, Alkylating/adverse effects/*therapeutic use
Brain Neoplasms/*drug therapy/pathology/radiotherapy
Dacarbazine/adverse effects/*analogs & derivatives/therapeutic use/toxicity
Female
Glioma/*drug therapy/pathology/radiotherapy
Hematologic Diseases/etiology
Humans
Male
Middle Aged
Nausea/drug therapy/etiology
Neoplasm Staging
Republic of Korea
Retrospective Studies
Severity of Illness Index
Sex Factors
Vomiting/drug therapy/etiology
Young Adult
Antineoplastic Agents, Alkylating
Dacarbazine

Reference

1. Stupp R, Dietrich PY, Ostermann Kraljevic S, Pica A, Maillard I, Maeder P, Meuli R, Janzer R, Pizzolato G, Miralbell R, et al. Promising survival for patients with newly diagnosed glioblastoma multiforme treated with concomitant radiation plus temozolomide followed by adjuvant temozolomide. J Clin Oncol. 2002; 20:1375–1382.

2. Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, Belanger K, Brandes AA, Marosi C, Bogdahn U, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 2005; 352:987–996.

3. Walker MD, Green SB, Byar DP, Alexander E Jr, Batzdorf U, Brooks WH, Hunt WE, MacCarty CS, Mahaley MS Jr, Mealey J Jr, et al. Randomized comparisons of radiotherapy and nitrosoureas for the treatment of malignant glioma after surgery. N Engl J Med. 1980; 303:1323–1329.

4. Athanassiou H, Synodinou M, Maragoudakis E, Paraskevaidis M, Verigos C, Misailidou D, Antonadou D, Saris G, Beroukas K, Karageorgis P. Randomized phase II study of temozolomide and radiotherapy compared with radiotherapy alone in newly diagnosed glioblastoma multiforme. J Clin Oncol. 2005; 23:2372–2377.

5. Khasraw M, Bell D, Wheeler H. Long-term use of temozolomide: could you use temozolomide safely for life in gliomas? J Clin Neurosci. 2009; 16:854–855.

6. Panet-Raymond V, Souhami L, Roberge D, Kavan P, Shakibnia L, Muanza T, Lambert C, Leblanc R, Del Maestro R, Guiot MC, et al. Accelerated hypofractionated intensity-modulated radiotherapy with concurrent and adjuvant temozolomide for patients with glioblastoma multiforme: a safety and efficacy analysis. Int J Radiat Oncol Biol Phys. 2009; 73:473–478.

7. Zwinkels H, Roon K, Jeurissen FJ, Taphoorn MJ, Hop WC, Vecht CJ. Management of temozolomide toxicity by nurse practitioners in neuro-oncology. Oncol Nurs Forum. 2009; 36:225–231.

8. Kesari S, Schiff D, Drappatz J, LaFrankie D, Doherty L, Macklin EA, Muzikansky A, Santagata S, Ligon KL, Norden AD, et al. Phase II study of protracted daily temozolomide for low-grade gliomas in adults. Clin Cancer Res. 2009; 15:330–337.

9. National Cancer Institute. CTCAE v3.0. accessed on 9 August 2006. Available at http://www.cancer.gov.

10. Hawkins R, Grunberg S. Chemotherapy-induced nausea and vomiting: challenges and opportunities for improved patient outcomes. Clin J Oncol Nurs. 2009; 13:54–64.

11. Middleton J, Lennan E. Effectively managing chemotherapy-induced nausea and vomiting. Br J Nurs. 2011; 20:S7–S8. S10–S12. S14–S15.

12. Stone P, Richards M, A'Hern R, Hardy J. Fatigue in patients with cancers of the breast or prostate undergoing radical radiotherapy. J Pain Symptom Manage. 2001; 22:1007–1015.

13. Poirier P. The impact of fatigue on role functioning during radiation therapy. Oncol Nurs Forum. 2011; 38:457–465.

14. Kuchinski AM, Reading M, Lash AA. Treatment-related fatigue and exercise in patients with cancer: a systematic review. Medsurg Nurs. 2009; 18:174–180.

15. Lee H, Lim Y, Yoo MS, Kim Y. Effects of a nurse-led cognitive-behavior therapy on fatigue and quality of life of patients with breast cancer undergoing radiotherapy: an exploratory study. Cancer Nurs. 2011; 34:E22–E30.

16. Young KE, White CA. The prevalence and moderators of fatigue in people who have been successfully treated for cancer. J Psychosom Res. 2006; 60:29–38.

17. Kim SG. Managements of chemotherapy induced nausea and vomiting. Korean J Clin Oncol. 2012; 8:23–29.

18. Song KH. Managements of chemotherapy induced nausea and vomiting. Korean J Med. 2012; 82:532–536.

19. Jordan K, Gralla R, Jahn F, Molassiotis A. International antiemetic guidelines on chemotherapy induced nausea and vomiting (CINV): content and implementation in daily routine practice. Eur J Pharmacol. 2014; 722:197–202.

20. Zeuner A, Signore M, Martinetti D, Bartucci M, Peschle C, De Maria R. Chemotherapy-induced thrombocytopenia derives from the selective death of megakaryocyte progenitors and can be rescued by stem cell factor. Cancer Res. 2007; 67:4767–4773.

21. Vadhan-Raj S. Management of chemotherapy-induced thrombocytopenia: current status of thrombopoietic agents. Semin Hematol. 2009; 46:S26–S32.